Published in Biotech Business Week, March 13th, 2006
Under a series of agreements, Arrow has granted King rights to certain current and future New Drug Applications (NDAs) regarding the Altace formulations and intellectual property, including patent rights and technology licenses relating to them. Under certain conditions, Arrow will be responsible for the manufacture and supply of new formulations of Altace for King. Additionally, King has granted Cobalt Pharmaceuticals, Inc. a non-exclusive right to enter into the U.S....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.